See more : Wall Street Media Co., Inc. (WSCO) Income Statement Analysis – Financial Results
Complete financial analysis of BrainsWay Ltd. (BWAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BrainsWay Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Sunvim Group Co.,Ltd (002083.SZ) Income Statement Analysis – Financial Results
- IQ-AI Limited (IQAI.L) Income Statement Analysis – Financial Results
- First Northern Community Bancorp (FNRN) Income Statement Analysis – Financial Results
- FastPartner AB (publ) (FPAR-A.ST) Income Statement Analysis – Financial Results
- Clean Seas Seafood Limited (CSS.AX) Income Statement Analysis – Financial Results
BrainsWay Ltd. (BWAY)
About BrainsWay Ltd.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.79M | 27.18M | 29.66M | 22.06M | 23.10M | 16.40M | 11.15M | 11.52M | 6.80M | 3.38M | 1.19M | 364.25K |
| Cost of Revenue | 8.31M | 7.13M | 6.60M | 5.06M | 5.13M | 3.59M | 2.60M | 2.43M | 1.47M | 656.00K | 199.00K | 46.07K |
| Gross Profit | 23.48M | 20.05M | 23.06M | 17.00M | 17.97M | 12.81M | 8.55M | 9.10M | 5.33M | 2.72M | 990.00K | 318.18K |
| Gross Profit Ratio | 73.86% | 73.77% | 77.75% | 77.07% | 77.80% | 78.11% | 76.72% | 78.94% | 78.44% | 80.59% | 83.26% | 87.35% |
| Research & Development | 6.67M | 7.68M | 6.39M | 5.82M | 7.88M | 6.16M | 5.34M | 3.79M | 4.10M | 6.44M | 3.69M | 5.97M |
| General & Administrative | 5.32M | 6.85M | 5.78M | 4.72M | 4.39M | 8.23M | 7.47M | 5.74M | 3.61M | 2.34M | 1.43M | 1.31M |
| Selling & Marketing | 16.46M | 18.20M | 15.88M | 11.28M | 13.27M | 3.11M | 1.83M | 1.21M | 1.93M | 1.21M | 633.00K | 140.34K |
| SG&A | 21.64M | 25.05M | 21.66M | 16.01M | 17.66M | 11.34M | 9.30M | 6.95M | 5.54M | 3.55M | 2.06M | 1.45M |
| Other Expenses | 133.00K | 0.00 | 0.00 | 0.00 | 916.00K | 427.00K | 523.00K | 426.00K | 200.00K | 11.00K | -504.00K | 0.00 |
| Operating Expenses | 28.44M | 32.73M | 28.06M | 21.83M | 26.45M | 17.92M | 15.16M | 11.17M | 9.84M | 10.00M | 5.26M | 5.95M |
| Cost & Expenses | 36.74M | 39.86M | 34.66M | 26.89M | 31.58M | 21.51M | 17.76M | 13.59M | 11.31M | 10.66M | 5.46M | 5.99M |
| Interest Income | 2.17M | 1.11M | 225.00K | 61.00K | 175.00K | 44.00K | 22.00K | 12.00K | 18.00K | 93.00K | 304.00K | 288.19K |
| Interest Expense | 48.00K | 46.00K | 1.42M | 319.00K | 398.00K | 354.00K | 360.00K | 404.00K | 98.00K | 525.00K | 283.00K | 0.00 |
| Depreciation & Amortization | 1.34M | 1.53M | 1.69M | 1.62M | 2.80M | 1.23M | 1.07M | 649.00K | 611.00K | 336.00K | 206.00K | 109.28K |
| EBITDA | -2.56M | -11.45M | -4.67M | -3.46M | -6.58M | -4.40M | -5.56M | -1.34M | -3.38M | -5.68M | -4.06M | -5.57M |
| EBITDA Ratio | -8.06% | -41.02% | -11.17% | -21.89% | -28.50% | -26.85% | -49.92% | -12.75% | -57.54% | -203.22% | -79.98% | -1,530.22% |
| Operating Income | -4.96M | -12.68M | -5.00M | -4.83M | -8.48M | -5.11M | -6.61M | -2.07M | -4.51M | -7.28M | -4.27M | -5.68M |
| Operating Income Ratio | -15.60% | -46.67% | -16.86% | -21.89% | -36.69% | -31.19% | -59.32% | -17.95% | -66.25% | -215.30% | -358.87% | -1,560.22% |
| Total Other Income/Expenses | 1.01M | -351.00K | -1.42M | -319.00K | -1.43M | -1.16M | -274.00K | -328.00K | 418.00K | 732.00K | -2.83M | -233.28K |
| Income Before Tax | -3.95M | -13.03M | -6.42M | -5.15M | -9.91M | -6.27M | -6.89M | -2.40M | -4.09M | -6.55M | -7.09M | -5.92M |
| Income Before Tax Ratio | -12.41% | -47.96% | -21.64% | -23.34% | -42.88% | -38.24% | -61.78% | -20.80% | -60.10% | -193.64% | -596.64% | -1,624.27% |
| Income Tax Expense | 251.00K | 315.00K | 43.00K | 237.00K | 422.00K | 209.00K | 169.00K | 404.00K | 98.00K | 525.00K | 28.00K | 0.00 |
| Net Income | -4.20M | -13.35M | -6.46M | -5.39M | -10.33M | -6.48M | -7.05M | -2.40M | -4.09M | -6.55M | -7.12M | -5.92M |
| Net Income Ratio | -13.20% | -49.12% | -21.79% | -24.41% | -44.71% | -39.51% | -63.29% | -20.80% | -60.10% | -193.64% | -598.99% | -1,624.27% |
| EPS | -0.13 | -0.43 | -0.21 | -0.24 | -0.50 | -0.39 | -0.48 | -0.17 | -0.28 | -0.46 | -0.55 | -0.49 |
| EPS Diluted | -0.13 | -0.43 | -0.21 | -0.24 | -0.50 | -0.39 | -0.48 | -0.17 | -0.28 | -0.46 | -0.55 | -0.49 |
| Weighted Avg Shares Out | 33.16M | 30.77M | 31.15M | 22.44M | 20.51M | 16.64M | 14.77M | 14.17M | 14.46M | 14.16M | 12.87M | 12.17M |
| Weighted Avg Shares Out (Dil) | 33.16M | 30.77M | 31.15M | 22.44M | 20.51M | 16.64M | 14.77M | 14.51M | 14.46M | 14.26M | 12.87M | 12.17M |
3 Stocks to Buy BEFORE They Become Wall Street Darlings
While higher risk, identifying promising emerging disruptors early on can be very lucrative. For investors who identify such companies when their valuations seem reasonable, game-changing returns can be possible, once the market eventually recognizes their potential.
BrainsWay: Profitability Is Within Sight
BrainsWay's Q2 results show continued revenue growth and improved cost control. The company is shifting its sales focus to larger institutions and enterprise customers, potentially improving sales efficiency. BrainsWay's market capitalization is still only approximately equal to its net cash...
Brainsway Ltd (BWAY) Q2 2023 Earnings Call Transcript
Brainsway Ltd (NASDAQ:BWAY ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co....
BrainsWay Reports Second Quarter 2023 Financial Results and Operational Highlights
BURLINGTON, Mass. and JERUSALEM, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported second quarter 2023 financial results and provided...
BrainsWay Announces Publication of Three New Deep TMS Research Publications
New Articles Enhance Understanding of Deep TMS Safety Profile and Survey Addiction Research New Articles Enhance Understanding of Deep TMS Safety Profile and Survey Addiction Research
BrainsWay Accelerates International Expansion in India
Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™ Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™
Brainsway Ltd. Sponsored ADR (BWAY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Brainsway Ltd. Sponsored ADR (BWAY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.
BrainsWay to Report First Quarter 2023 Financial Results on May 17, 2023
BURLINGTON, Mass. and JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first...
BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023
BURLINGTON, Mass. and JERUSALEM, Israel, March 01, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its...
Why I Am Passing On BrainsWay And Neuronetics
I am bullish on the niche industry that uses magnetic stimulation for brain therapies. BrainsWay and Neuronetics are US-listed stocks in this niche, however they are highly unprofitable with volatile sales growth.
Source: https://incomestatements.info
Category: Stock Reports